Clinical pharmacokinetics and pharmacodynamics of Nicardipine; a systematic review.

IF 3.9 3区医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY

Expert Opinion on Drug Metabolism & Toxicology Pub Date : 2024-09-09 DOI:10.1080/17425255.2024.2402481

Ammara Ayub,Ammara Zamir,Imran Imran,Hamid Saeed,Abdul Majeed,Majid Aziz,Faleh Alqahtani,Muhammad Fawad Rasool

{"title":"Clinical pharmacokinetics and pharmacodynamics of Nicardipine; a systematic review.","authors":"Ammara Ayub,Ammara Zamir,Imran Imran,Hamid Saeed,Abdul Majeed,Majid Aziz,Faleh Alqahtani,Muhammad Fawad Rasool","doi":"10.1080/17425255.2024.2402481","DOIUrl":null,"url":null,"abstract":"INTRODUCTION\r\nNicardipine is a type of calcium channel blocker that is commonly used in the treatment of angina pectoris, hypertension, and related cardiovascular disorders. This systematic review assesses the reported pharmacokinetic (PK) and associated pharmacodynamic (PD) parameters of nicardipine in humans.\r\n\r\nAREAS COVERED\r\nAn exhaustive literature search using four internet databases was conducted up to 5 October 2023, which yielded 871 papers, of which 32 fulfilled the eligibility requirements by including human PK and related PD data. The area under the plasma concentration vs. time curve from zero to infinity (AUC0-∞) and maximum plasma concentration (Cmax) of nicardipine rise proportionately with increasing dosage. One study revealed that AUC0-∞ of nicardipine was increased by 5-fold in hepatic cirrhosis patients compared to the control subjects. Moreover, related PD data in renal-impaired hypertensive patients revealed that a notable reduction in blood pressure was associated with nicardipine administration.\r\n\r\nEXPERT OPINION\r\nThis review covers comprehensive data on clinical PK, drug-drug interaction studies, effects of dosage form on ADME, and associated PD parameters of nicardipine using all relevant published studies. The present study will also aid in the development and evaluation of PK models for suggesting model-informed dosing regimens.\r\n\r\nPROSPERO NUMBER\r\nCRD42024533051.","PeriodicalId":12250,"journal":{"name":"Expert Opinion on Drug Metabolism & Toxicology","volume":"16 1","pages":""},"PeriodicalIF":3.9000,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Drug Metabolism & Toxicology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17425255.2024.2402481","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

INTRODUCTION Nicardipine is a type of calcium channel blocker that is commonly used in the treatment of angina pectoris, hypertension, and related cardiovascular disorders. This systematic review assesses the reported pharmacokinetic (PK) and associated pharmacodynamic (PD) parameters of nicardipine in humans. AREAS COVERED An exhaustive literature search using four internet databases was conducted up to 5 October 2023, which yielded 871 papers, of which 32 fulfilled the eligibility requirements by including human PK and related PD data. The area under the plasma concentration vs. time curve from zero to infinity (AUC0-∞) and maximum plasma concentration (Cmax) of nicardipine rise proportionately with increasing dosage. One study revealed that AUC0-∞ of nicardipine was increased by 5-fold in hepatic cirrhosis patients compared to the control subjects. Moreover, related PD data in renal-impaired hypertensive patients revealed that a notable reduction in blood pressure was associated with nicardipine administration. EXPERT OPINION This review covers comprehensive data on clinical PK, drug-drug interaction studies, effects of dosage form on ADME, and associated PD parameters of nicardipine using all relevant published studies. The present study will also aid in the development and evaluation of PK models for suggesting model-informed dosing regimens. PROSPERO NUMBER CRD42024533051.

查看原文本刊更多论文

尼卡地平的临床药代动力学和药效学；系统综述。

简介尼卡地平是一种钙通道阻滞剂，常用于治疗心绞痛、高血压和相关心血管疾病。本系统综述评估了尼卡地平在人体中的药代动力学（PK）和相关药效学（PD）参数。涵盖领域截至 2023 年 10 月 5 日，我们使用四个互联网数据库进行了详尽的文献检索，共获得 871 篇论文，其中 32 篇符合资格要求，包括人体 PK 和相关 PD 数据。尼卡地平的血浆浓度与从零到无穷大的时间曲线下面积（AUC0-∞）和最大血浆浓度（Cmax）随剂量的增加而成正比上升。一项研究显示，与对照组相比，肝硬化患者体内尼卡地平的 AUC0-∞ 增加了 5 倍。此外，肾功能受损的高血压患者的相关 PD 数据显示，服用尼卡地平可显著降低血压。专家观点本综述利用所有已发表的相关研究，涵盖了尼卡地平的临床 PK、药物相互作用研究、剂型对 ADME 的影响以及相关 PD 参数的全面数据。本研究还将有助于开发和评估 PK 模型，从而提出以模型为依据的用药方案。PROSPERO NUMBERCRD42024533051。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Opinion on Drug Metabolism & Toxicology 医学-生化与分子生物学

CiteScore

7.90

自引率

2.30%

发文量

审稿时长

4-8 weeks

期刊介绍： Expert Opinion on Drug Metabolism & Toxicology (ISSN 1742-5255 [print], 1744-7607 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on all aspects of ADME-Tox. Each article is structured to incorporate the author’s own expert opinion on the scope for future development. The Editors welcome: Reviews covering metabolic, pharmacokinetic and toxicological issues relating to specific drugs, drug-drug interactions, drug classes or their use in specific populations; issues relating to enzymes involved in the metabolism, disposition and excretion of drugs; techniques involved in the study of drug metabolism and toxicology; novel technologies for obtaining ADME-Tox data. Drug Evaluations reviewing the clinical, toxicological and pharmacokinetic data on a particular drug. The audience consists of scientists and managers in the pharmaceutical industry, pharmacologists, clinical toxicologists and related professionals.